- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Pasithea Therapeutics to Present Updated Data from Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients at the 2025 ASCO Annual Meeting | 4 | GlobeNewswire (USA) | ||
| 10.04. | Pasithea Therapeutics Stock Climbs 41% On Positive Clinical Safety Recommendation | - | RTTNews | ||
| 10.04. | Pre-market Movers: InnovAge, Venus Concept, Pasithea Therapeutics, Full House Resorts, Antelope Enterprise | 429 | AFX News | OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 09.05 A.M. ET).In the Green InnovAge Holding Corp (INNV) is up over 58% at $4.45.
Pasithea... ► Artikel lesen | |
| 10.04. | Pasithea Therapeutics macht Fortschritte bei Krebsmedikamenten-Studie | 3 | Investing.com Deutsch | ||
| 10.04. | Pasithea Therapeutics progresses with cancer drug trial | 2 | Investing.com | ||
| PASITHEA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 10.04. | Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its Ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer | 67 | GlobeNewswire (Europe) | - SRC recommended that the trial escalate to the next dose level of 30mg capsule - - No dose-limiting toxicities (DLT's) or rash observed to date - MIAMI, April 10, 2025 (GLOBE NEWSWIRE) -- Pasithea... ► Artikel lesen | |
| 24.03. | Pasithea Therapeutics Corp. - 10-K, Annual Report | - | SEC Filings | ||
| 06.02. | Pre-market Movers: Lipella Pharmaceuticals, Invivyd, Beasley Broadcast Group, Pasithea Therapeutics, Skyworks Solutions | 635 | AFX News | OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 07.55 A.M. ET).In the Green Lipella Pharmaceuticals Inc. (LIPO) is up over 180%... ► Artikel lesen | |
| 05.02. | Pre-market Movers: Pasithea Therapeutics, EyePoint Pharmaceuticals, Samfine Creation, Volcon, Adicet Bio | 597 | AFX News | SUNNYVALE (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 08.00 A.M. ET).In the Green Pasithea Therapeutics Corp. (KTTA) is up over... ► Artikel lesen | |
| 05.02. | Pasithea's PAS-004 advances in cancer trial with no toxicities | 5 | Investing.com | ||
| 05.02. | Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer | 209 | GlobeNewswire (Europe) | SRC recommended that the trial escalate to the next dose level of 22mg capsuleNo dose-limiting toxicities (DLT's) or rash observed to date in either capsule or tablet formulations MIAMI, Feb. 05... ► Artikel lesen | |
| 14.01. | Pasithea Therapeutics Announces Opening of European Clinical Trial Sites and Completes Initial Dosing of Cohort 4 | 2 | GlobeNewswire (USA) | ||
| 26.11.24 | Pasithea Therapeutics Corp. - 8-K, Current Report | 1 | SEC Filings | ||
| 20.11.24 | Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer | 1 | GlobeNewswire (USA) | ||
| 13.11.24 | Pasithea Therapeutics Corp. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 26.09.24 | Pasithea Therapeutics Announces Positive Initial Safety, Tolerability, Pharmacokinetic (PK), and Preliminary Efficacy Data from its Phase 1 Clinical Trial of PAS-004 in Advanced Cancer | 193 | GlobeNewswire (Europe) | -- Single patient in 2mg cohort with stage 3 colon cancer who received 4 prior lines of therapy achieves prolonged stable disease and remains on drug into 6th dosing cycle -- -- No treatment-related... ► Artikel lesen |
16 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| OCUGEN | 0,660 | +2,14 % | Ocugen Aktie: Leichte Erholung nach schwierigem Jahr | Trotz langfristiger Verluste halten Analysten an positiven Bewertungen für Ocugen fest. Die Gentherapie-Pipeline bleibt der zentrale Hoffnungsträger. Die Ocugen-Aktie zeigt heute eine leichte Erholung... ► Artikel lesen | |
| GENPREX | 1,820 | -100,00 % | Genprex presents promising gene therapy data for lung cancer | ||
| QIAGEN | 37,375 | -0,62 % | UBS stuft QIAGEN NV auf 'Neutral' | ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat die Einstufung für Qiagen bei einem Kursziel von 48 US-Dollar auf "Neutral" belassen. Die Ziele seien bestätigt worden, nähere Details seien... ► Artikel lesen | |
| BIONTECH | 101,00 | -1,17 % | BioNTech SE: BioNTech veröffentlicht am 5. Mai 2025 Ergebnisse für das erste Quartal 2025 und informiert über operativen Fortschritt | MAINZ, Deutschland, 22. April 2025(Nasdaq: BNTX, "BioNTech" oder "das Unternehmen") wird am Montag, den 5. Mai 2025, die Ergebnisse für das erste Quartal 2025 veröffentlichen. Darüber hinaus wird das... ► Artikel lesen | |
| EVOTEC | 7,216 | -1,74 % | Evotec: Neue Strategie und starkes Ergebnis im vierten Quartal! | ||
| SPRINGWORKS THERAPEUTICS | 44,550 | -0,98 % | Hohes Potenzial: Merck KGaA vor Milliarden-Deal: US-Krebsspezialist SpringWorks im Visier | © Foto: Arne Dedert/dpaDer deutsche Pharmakonzern Merck plant den Kauf eines vielversprechenden US-Wettbewerbers. Die Gelegenheit ist günstig.Der Darmstädter Pharma- und Technologiekonzern Merck KGaA... ► Artikel lesen | |
| OLEMA PHARMACEUTICALS | 5,100 | 0,00 % | Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN FRANCISCO, April 02, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. ("Olema" or "Olema Oncology", Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development... ► Artikel lesen | |
| ADMA BIOLOGICS | 22,260 | -0,36 % | ADMA Biologics, Inc.: ADMA Biologics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update | FY 2024 Total Revenue of $426.5 Million, a 65% YoY Increase FY 2024 GAAP Net Income of $197.7 Million, Including an $84.3 Million Valuation Allowance Tax Benefit FY 2024 Adjusted EBITDA(1)... ► Artikel lesen | |
| TOURMALINE BIO | 17,320 | 0,00 % | Cantor Fitzgerald maintains Overweight on Tourmaline Bio stock | ||
| HUMACYTE | 1,480 | 0,00 % | Humacyte, Inc: Humacyte Announces Fourth Quarter and Year End 2024 Financial Results and Provides Business Update | - Received U.S. Food and Drug Administration (FDA) approval of Symvess (acellular tissue engineered vessel-tyod) for the treatment of extremity vascular trauma - - Commenced market launch and first... ► Artikel lesen | |
| BB BIOTECH | 30,050 | -0,83 % | BB Biotech Aktie: Vor Quartalszahlen unter Druck | BB Biotech verzeichnet deutliche Kursverluste, doch Analysten halten an positiven Erwartungen fest. Die anstehenden Quartalszahlen könnten neue Impulse bringen. Die BB Biotech-Aktie zeigt sich vor der... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 5,685 | -1,13 % | Recursion Pharmaceuticals: Recursion to Present Preliminary Clinical Data from the Ongoing Phase 1b/2 trial of REC-4881 in FAP at Digestive Disease Week 2025 | ||
| AMYLYX PHARMACEUTICALS | 5,240 | 0,00 % | Gubra A/S: Gubra Announces New Collaboration with Amylyx Pharmaceuticals to Develop a Novel Long-acting GLP-1 Receptor Antagonist | Today, Gubra A/S ("Company"), a company specializing in pre-clinical contract research services and peptide-based drug discovery within metabolic and fibrotic diseases, announced a collaboration with... ► Artikel lesen | |
| JANUX THERAPEUTICS | 32,090 | 0,00 % | Pre-market Movers: Cheetah Net Supply Chain Service, NLS Pharmaceutics, PSQ Holdings, Janux Therapeutics, Coherus BioSciences | CANBERA (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 08.45 A.M. ET).In the Green Cheetah Net Supply Chain Service Inc. (CTNT) is up... ► Artikel lesen | |
| 2SEVENTY BIO | 4,990 | 0,00 % | Pre-market Movers: 2seventy bio, Sonoma Pharmaceuticals, Tenon Medical, Arvinas, NET Power Inc. | LONDON (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 09.00 A.M. ET).In the Green 2seventy bio, Inc. (TSVT) is up over 76% at $4.93.
Sonoma... ► Artikel lesen |
Das Unternehmen PASITHEA THERAPEUTICS CORP kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 1,735 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PASITHEA THERAPEUTICS CORP finden Sie auf Wallstreet Online.
